Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

999.84
-1.5100-0.15%
Pre-market: 997.00-2.8400-0.28%06:18 EDT
Volume:1.45M
Turnover:1.44B
Market Cap:945.23B
PE:43.57
High:1,002.93
Open:1,000.03
Low:990.30
Close:1,001.35
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.56
T/O Rate:0.15%
Dividend:6.00
Dividend Rate:0.60%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:35.62
PE(LYR):43.57

Loading ...

Market Chatter: Novo Nordisk Spends Double on US Advertising for GLP-1 Drugs Than Lilly

MT Newswires Live
·
Jan 28

Novo Spends Double on US Advertising for GLP-1 Drugs Than Lilly, Reuters Reports

MT Newswires Live
·
Jan 28

Eli Lilly Signed Over $1.12 Billion Deal to Develop Hearing Loss Treatments, Seamless Therapeutics Says

MT Newswires Live
·
Jan 28

Novo Nordisk's US Advertising Spend for Semaglutide Drugs Doubles Eli Lilly's

Deep News
·
Jan 28

BRIEF-Seamless Therapeutics Announces Global Research Collaboration With Lilly To Develop Programmable Recombinase-Based Therapeutics For Hearing Loss

Reuters
·
Jan 28

Seamless: Eligible for Over $1.12 Bln, Including Potential Development and Commercial Milestone Payments as Part of Collaboration

THOMSON REUTERS
·
Jan 28

Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless

Reuters
·
Jan 28

Merck veteran Perlmutter-led Eikon ‍Therapeutics eyes $908 million valuation in IPO

Reuters
·
Jan 28

CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks

TIPRANKS
·
Jan 28

Medpal AI Plc - Unit Approved to Purchase Eli Lilly Products in UK

THOMSON REUTERS
·
Jan 28

Medpal AI Plc - to Dispense Eli Lilly's Mounjaro in UK

THOMSON REUTERS
·
Jan 28

US names HIV, arthritis drugs for next Medicare price talks

Reuters
·
Jan 28

CMS: Drugs Selected for Third Cycle of Medicare Drug Price Negotiation Are Rexulti, Trulicity, Verzenio, Xeljanz; Xeljanz Xr and Xolair

THOMSON REUTERS
·
Jan 28

Eli Lilly & Co. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Jan 28

Eli Lilly's Jaypirca Gets Approval in Canada for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia

MT Newswires Live
·
Jan 28

Citigroup Maintains Street-High $1,500 Price Target on Eli Lilly Stock (LLY)

TIPRANKS
·
Jan 28

Eli Lilly’s Pirtobrutinib Trial Completion Signals Next Phase in the BTK Inhibitor Race

TIPRANKS
·
Jan 28

Jaypirca® (Pirtobrutinib), the First and Only Non-Covalent (Reversible) Btk Inhibitor, NOW Available in Canada for Adult Patients With Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

THOMSON REUTERS
·
Jan 27

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Pennant Group (PNTG) and Warby Parker (WRBY)

TIPRANKS
·
Jan 27

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

Dow Jones
·
Jan 27